Clinical Trials

Clinical Trials

The intensive clinical activity of the IOV is carried out by hospital and university doctors who use cutting-edge treatment programs, with the most accredited conventional cancer treatments. This clinical activity is flanked and complemented by an equally lively research activity that leads to the acquisition of new knowledge for the progress of medicine and offers the possibility to use innovative experimental therapies as therapeutic alternatives, in particular, in patients in whom conventional drugs have failed or have been found to be poorly effective.

This last aspect is achieved thanks to the continuous participation of IOV in clinical trials, both national and international, which involve the use of non-commercialized medicines that are not available on the Italian market. In addition, the Institute’s medical specialists promote, design and carry out clinical trials that explore possible new indications of drugs already on the market, in order to test new therapeutic strategies and thus offer further possibilities of cure.

All clinical trials, whether promoted by the pharmaceutical industry or by non-profit organizations, are conducted at IOV according to strict ethical, regulatory and quality standards. Before being started, each trial must be approved by the Ethics Committee for clinical trials, in accordance with the regulations on clinical trials, the dictates of good clinical practice (GCP) and the ethical principles indicated in the Helsinki Declaration.

For the patients included in the experimental protocols, the main care reference is the research nurses, who represent a flagship of the scientific activity of the IOV, one of only two Italian centers to have this professional figure.

The levels of research, diagnosis and treatment conducted in the Institute place the IOV among the most accredited cancer centers nationwide.

IN-BIO NF STUDIO PILOTA-RICERCA DI INDICATORI PRECOCI DI MALIGNITA’ IN BIOPSIE LIQUIDE IN PAZIENTI AFFETTI DA NEUROFIBROMATOSI DI TIPO 1

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
IN-BIO-NF
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Osservazionale
Fase
.
Unità Operativa
Immunologia e diagnostica molecolare oncologica
Principal Investigator
Dott.ssa Federica Chiara

MASTER FRAMEWORK FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA – A PROSPECTIVE OBSERVATIONAL STUDY OF TREATMENT OUTCOMES

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
IRST204.08 (IMPACT STREAM)
Codice EudraCT
NP
Sponsor/Promotore
IRST - Meldola
Tipologia
Osservazionale
Fase
.
Unità Operativa
Oncoematologia - CF
Principal Investigator

Raccolta di evidenze dalla pratica clinica reale sull’Efficacia di Pembrolizumab nel carcinoma mammario triplo negativo in stadio precoce – Studio GAMBIT

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
GAMBIT
Codice EudraCT
NP
Sponsor/Promotore
DISCOG Università di Padova
Tipologia
Osservazionale
Fase
.
Unità Operativa
Oncologia 2
Principal Investigator

SPECIFIQA- studio ambispettico, osservazionale, multicentrico, no profit

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
IOV-SPECIFIQA
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Osservazionale
Fase
.
Unità Operativa
Fisica sanitaria
Principal Investigator

Impatto del sesso su tossicità ed efficacia delle terapie antitumorali in pazienti trattati per sarcoma presso un Centro di riferimento – SEx Differences In Toxicity and Outcomes in patients treated for Sarcoma in a reference center (SEDITOS)

Patologie
Stato
Aperto - reclutamento in corso
Codice studio
SEDITOS
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Sviluppo di nuove strategie combinatorie per superare la resistenza ai farmaci nelle Leucemie Mieloidi Acute (AML)

Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
DELIVERANCE
Codice EudraCT
NP
Sponsor/Promotore
IOV
Tipologia
Osservazionale
Fase
.
Unità Operativa
Principal Investigator

Search

Status

Last modified: 06/04/2021 15:13

Scroll to Top